<DOC>
	<DOCNO>NCT00889967</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Ciprofloxacin Inhalation treatment patient non-cystic fibrosis ( CF ) bronchiectasis .</brief_summary>
	<brief_title>Safety Efficacy Study Ciprofloxacin Inhalation Patients With Non-Cystic Fibrosis Bronchiectasis `` ORBIT-1 ''</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>1 . Are willing able provide write informed consent . 2 . Are male female 18 80 year age , inclusive . 3 . Have confirm diagnosis nonCF bronchiectasis per high resolution compute tomography ( HRCT ) least 4 year . 4 . Confirmation infection P. aeruginosa screen 1 . Have know local systemic hypersensitivity fluoroquinolone quinolone antibiotic . 2 . Have exacerbation Screening Phase define require treatment inhale , oral , intravenous antibiotic prior first dose study drug . 3 . Have diagnosis cystic fibrosis.. 4 . Have change either treatment regimen initiation treatment follow medication within 28 day prior Visit 1 : Azithromycin Hypertonic saline Bronchodilator medication Oral corticosteroid . 5 . Have receive investigational drug device within 28 day prior Visit 1 . 6 . Have serious active medical psychiatric illness , opinion investigator , would interfere patient ' treatment , assessment , compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>antimicrobial</keyword>
	<keyword>inhalation</keyword>
	<keyword>ciprofloxacin</keyword>
	<keyword>Non-Cystic Fibrosis Bronchiectasis</keyword>
</DOC>